Some multinationals to stage uphill battle in maintaining initial insurance price

Published: 2008-07-25 06:58:00

Updated: 2008-07-25 06:58:00

Despite their favorable ruling over the trial to confirm the scope of patent rights, some multinational drug manufacturers, such as Pfizer and Sanofi-Aventis, are unlikely to see their reduced insurance prices to the initial level, according to the Ministry of Health, Welfare and Family Affairs.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK